Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in
different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may
be an effective treatment for recurrent Paget's disease.
PURPOSE: This clinical trial is studying how well topical imiquimod works in treating
patients with recurrent Paget's disease of the vulva.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Cancer Institute (NCI) Ohio State University